{
  "metadata": {
    "source": "expert_curation",
    "created_date": "2025-09-03",
    "description": "Sample ground truth dataset for NSCLC medications",
    "expert": "clinical_pharmacist",
    "total_entries": 50
  },
  "entries": [
    {
      "medication": "pembrolizumab",
      "drug_class": "taking_pembrolizumab", 
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "PD-1 inhibitor, FDA approved for NSCLC",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "keytruda",
      "drug_class": "taking_pembrolizumab",
      "confidence": 1.0,
      "source": "expert_validation", 
      "notes": "Brand name for pembrolizumab",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "osimertinib",
      "drug_class": "taking_osimertinib",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "EGFR inhibitor for EGFR-positive NSCLC",
      "validated_by": "clinical_expert", 
      "validated_at": "2025-09-03"
    },
    {
      "medication": "tagrisso",
      "drug_class": "taking_osimertinib",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "Brand name for osimertinib",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "nivolumab",
      "drug_class": "taking_nivolumab",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "PD-1 inhibitor for NSCLC immunotherapy",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "opdivo",
      "drug_class": "taking_nivolumab", 
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "Brand name for nivolumab",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "atezolizumab",
      "drug_class": "taking_atezolizumab",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "PD-L1 inhibitor for NSCLC", 
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "tecentriq", 
      "drug_class": "taking_atezolizumab",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "Brand name for atezolizumab",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "carboplatin",
      "drug_class": "taking_carboplatin",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "Platinum-based chemotherapy for NSCLC",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "paclitaxel",
      "drug_class": "taking_paclitaxel",
      "confidence": 1.0, 
      "source": "expert_validation",
      "notes": "Taxane chemotherapy for NSCLC",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "taxol",
      "drug_class": "taking_paclitaxel",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "Brand name for paclitaxel",
      "validated_by": "clinical_expert", 
      "validated_at": "2025-09-03"
    },
    {
      "medication": "abraxane",
      "drug_class": "taking_paclitaxel",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "Nab-paclitaxel formulation",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "pemetrexed",
      "drug_class": "taking_pemetrexed",
      "confidence": 1.0,
      "source": "expert_validation", 
      "notes": "Antimetabolite chemotherapy for non-squamous NSCLC",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "alimta",
      "drug_class": "taking_pemetrexed",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "Brand name for pemetrexed",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "crizotinib",
      "drug_class": "taking_crizotinib", 
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "ALK inhibitor for ALK-positive NSCLC",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "xalkori",
      "drug_class": "taking_crizotinib",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "Brand name for crizotinib",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "alectinib",
      "drug_class": "taking_alectinib",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "ALK inhibitor, second-generation",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "alecensa",
      "drug_class": "taking_alectinib",
      "confidence": 1.0,
      "source": "expert_validation", 
      "notes": "Brand name for alectinib",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "erlotinib",
      "drug_class": "taking_erlotinib",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "EGFR inhibitor, first-generation",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    },
    {
      "medication": "tarceva",
      "drug_class": "taking_erlotinib",
      "confidence": 1.0,
      "source": "expert_validation",
      "notes": "Brand name for erlotinib",
      "validated_by": "clinical_expert",
      "validated_at": "2025-09-03"
    }
  ]
}